ATRA
INSIDER BUYINSIDER SELLAtara Biotherapeutics, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeAtara's flagship tabelecleucel program faces significant regulatory uncertainty following a second FDA Complete Response Letter in January 2026, though a strengthened BLA resubmission in September 2026 has been accepted with priority review (PDUFA target January 10, 2027). Q2 2026 showed mixed results (EPS miss of $0.06, revenue beat) amid senior leadership transitions in accounting and board roles, reflecting operational instability during a critical regulatory inflection point.
Red flags
- •Second FDA Complete Response Letter (January 2026) questioning adequacy of ALLELE study for accelerated approval
- •Extended regulatory timeline with multiple resubmissions since July 2025, indicating significant FDA concerns
- •EPS miss in Q2 2026 ($0.32 vs. consensus)
- •Chief Accounting Officer departure (effective July 17, 2026) during pre-approval phase
- •Minimal commercialization revenue ($630K in Q2) despite lead program in approval process
- •Low cash position ($21M assets) with no clear path to profitability pending regulatory decision
Insider Activity
Fund 13D/13G Filings (2)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).